» Articles » PMID: 37117846

Applications of Single-cell RNA Sequencing in Drug Discovery and Development

Abstract

Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods, together with associated computational tools and the growing availability of public data resources, are transforming drug discovery and development. New opportunities are emerging in target identification owing to improved disease understanding through cell subtyping, and highly multiplexed functional genomics screens incorporating scRNA-seq are enhancing target credentialling and prioritization. ScRNA-seq is also aiding the selection of relevant preclinical disease models and providing new insights into drug mechanisms of action. In clinical development, scRNA-seq can inform decision-making via improved biomarker identification for patient stratification and more precise monitoring of drug response and disease progression. Here, we illustrate how scRNA-seq methods are being applied in key steps in drug discovery and development, and discuss ongoing challenges for their implementation in the pharmaceutical industry.

Citing Articles

Single-Cell Sequencing: Genomic and Transcriptomic Approaches in Cancer Cell Biology.

Ortega-Batista A, Jaen-Alvarado Y, Moreno-Labrador D, Gomez N, Garcia G, Guerrero E Int J Mol Sci. 2025; 26(5).

PMID: 40076700 PMC: 11901077. DOI: 10.3390/ijms26052074.


Analyze the Diversity and Function of Immune Cells in the Tumor Microenvironment From the Perspective of Single-Cell RNA Sequencing.

Ma L, Luan Y, Lu L Cancer Med. 2025; 14(5):e70622.

PMID: 40062730 PMC: 11891933. DOI: 10.1002/cam4.70622.


MolGene-E: Inverse Molecular Design to Modulate Single Cell Transcriptomics.

Ohlan R, Murugan R, Xie L, Mottaqi M, Zhang S, Xie L bioRxiv. 2025; .

PMID: 40060426 PMC: 11888154. DOI: 10.1101/2025.02.19.638723.


An Ocular Gene-Set Expression Library for Heritability Partition and Cell Line Enrichment Analyses.

Hysi P, Hammond C Invest Ophthalmol Vis Sci. 2025; 66(3):11.

PMID: 40042876 PMC: 11892535. DOI: 10.1167/iovs.66.3.11.


Old drugs, new challenges: reassigning drugs for cancer therapies.

Czechowicz P, Wiech-Walow A, Slawski J, Collawn J, Bartoszewski R Cell Mol Biol Lett. 2025; 30(1):27.

PMID: 40038587 PMC: 11881393. DOI: 10.1186/s11658-025-00710-0.


References
1.
DiMasi J, Grabowski H, Hansen R . Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016; 47:20-33. DOI: 10.1016/j.jhealeco.2016.01.012. View

2.
Wouters O, Mckee M, Luyten J . Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020; 323(9):844-853. PMC: 7054832. DOI: 10.1001/jama.2020.1166. View

3.
Paul S, Mytelka D, Dunwiddie C, Persinger C, Munos B, Lindborg S . How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010; 9(3):203-14. DOI: 10.1038/nrd3078. View

4.
Nelson M, Tipney H, Painter J, Shen J, Nicoletti P, Shen Y . The support of human genetic evidence for approved drug indications. Nat Genet. 2015; 47(8):856-60. DOI: 10.1038/ng.3314. View

5.
Sernoskie S, Jee A, Uetrecht J . The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions. Pharmacol Rev. 2021; 73(3):861-896. DOI: 10.1124/pharmrev.120.000090. View